CN111991570B - 一种FAP-α特异性肿瘤诊断SPECT显像剂 - Google Patents
一种FAP-α特异性肿瘤诊断SPECT显像剂 Download PDFInfo
- Publication number
- CN111991570B CN111991570B CN202010725069.6A CN202010725069A CN111991570B CN 111991570 B CN111991570 B CN 111991570B CN 202010725069 A CN202010725069 A CN 202010725069A CN 111991570 B CN111991570 B CN 111991570B
- Authority
- CN
- China
- Prior art keywords
- tumor
- fap
- hfapi
- compound
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 238000002603 single-photon emission computed tomography Methods 0.000 title claims abstract description 36
- 239000012216 imaging agent Substances 0.000 title claims abstract description 24
- 238000003745 diagnosis Methods 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- VYFPSYVVFFFYBF-UHFFFAOYSA-N sodium;triphenylphosphane Chemical compound [Na].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VYFPSYVVFFFYBF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 10
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 8
- 239000007997 Tricine buffer Substances 0.000 claims description 8
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000001384 succinic acid Substances 0.000 claims description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 16
- 239000003446 ligand Substances 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 4
- -1 modified N-4-quinolyl-glycine- (2S) -cyanoproline skeleton small molecule Chemical class 0.000 abstract description 3
- 238000009826 distribution Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- BLTXUMDEYLYXLJ-UHFFFAOYSA-N OCN(C)CC(O)=O.OCC(CO)(CO)NCC(O)=O Chemical compound OCN(C)CC(O)=O.OCC(CO)(CO)NCC(O)=O BLTXUMDEYLYXLJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 description 25
- 239000003814 drug Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000002285 radioactive effect Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- 229910001868 water Inorganic materials 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000013170 computed tomography imaging Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 4
- 238000011729 BALB/c nude mouse Methods 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- WUYQBXHBLXPWNV-BYPYZUCNSA-N (2s)-4,4-difluoropyrrolidine-2-carbonitrile Chemical compound FC1(F)CN[C@H](C#N)C1 WUYQBXHBLXPWNV-BYPYZUCNSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FLZLJEOVXVLPRG-NSHDSACASA-N CC(C)(C)N(CC(N(CC(C1)(F)F)[C@@H]1C#N)=O)C(OC(C)(C)C)=O Chemical compound CC(C)(C)N(CC(N(CC(C1)(F)F)[C@@H]1C#N)=O)C(OC(C)(C)C)=O FLZLJEOVXVLPRG-NSHDSACASA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- FBQFSNRSVLFGLE-LURJTMIESA-N tert-butyl (2s)-2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)C[C@H]1C(N)=O FBQFSNRSVLFGLE-LURJTMIESA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- BENKAPCDIOILGV-MLWJPKLSSA-N (2s)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(O)C[C@H]1C(O)=O BENKAPCDIOILGV-MLWJPKLSSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- KBBYDJRXNXHGLM-UHFFFAOYSA-N 6-[3-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]propoxy]quinoline-4-carboxylic acid Chemical compound O(C1=CC2=C(C(=O)O)C=CN=C2C=C1)CCCN1CCN(CC1)C(=O)OC(C)(C)C KBBYDJRXNXHGLM-UHFFFAOYSA-N 0.000 description 1
- UVKYGKPXDDWMIV-UHFFFAOYSA-N 6-hydroxyquinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC=NC2=C1 UVKYGKPXDDWMIV-UHFFFAOYSA-N 0.000 description 1
- ZXFWGSFSRPLSRU-KRWDZBQOSA-N C(#N)[C@H]1N(CC(C1)(F)F)C(CNC(=O)C1=CC=NC2=CC=C(C=C12)OCCCN1CCNCC1)=O Chemical compound C(#N)[C@H]1N(CC(C1)(F)F)C(CNC(=O)C1=CC=NC2=CC=C(C=C12)OCCCN1CCNCC1)=O ZXFWGSFSRPLSRU-KRWDZBQOSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 241000483399 Ipimorpha retusa Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- NTWTZOALCQTKGI-UHFFFAOYSA-N N1=CC(C(=O)O)=CC=C1NN=CC1=CC=CC=C1S(O)(=O)=O Chemical compound N1=CC(C(=O)O)=CC=C1NN=CC1=CC=CC=C1S(O)(=O)=O NTWTZOALCQTKGI-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001440127 Phyllodes Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 1
- 238000003904 radioactive pollution Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- ISGKNURQVBUGBO-MLWJPKLSSA-N tert-butyl (2s)-2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C[C@H]1C(N)=O ISGKNURQVBUGBO-MLWJPKLSSA-N 0.000 description 1
- GFCHZNWKGRGZBJ-ZETCQYMHSA-N tert-butyl (2s)-2-carbamoyl-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(N)=O GFCHZNWKGRGZBJ-ZETCQYMHSA-N 0.000 description 1
- NZUSVVISTGILKC-ZETCQYMHSA-N tert-butyl (2s)-2-cyano-4,4-difluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)C[C@H]1C#N NZUSVVISTGILKC-ZETCQYMHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010725069.6A CN111991570B (zh) | 2020-07-24 | 2020-07-24 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
PCT/CN2021/107347 WO2022017375A1 (zh) | 2020-07-24 | 2021-07-20 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010725069.6A CN111991570B (zh) | 2020-07-24 | 2020-07-24 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111991570A CN111991570A (zh) | 2020-11-27 |
CN111991570B true CN111991570B (zh) | 2021-05-18 |
Family
ID=73467539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010725069.6A Active CN111991570B (zh) | 2020-07-24 | 2020-07-24 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111991570B (zh) |
WO (1) | WO2022017375A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991570B (zh) * | 2020-07-24 | 2021-05-18 | 北京大学 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
CN112409414B (zh) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | 锝-99m标记含异腈的FAPI衍生物及制备方法和应用 |
CN112625065A (zh) * | 2020-12-22 | 2021-04-09 | 北京师范大学 | 锝-99m标记含肼基尼古酰胺基的FAPI衍生物及制备方法和应用 |
CN117545481A (zh) * | 2021-02-01 | 2024-02-09 | 五一一制药股份有限公司 | 成纤维细胞活化蛋白-α显像剂的放射性标记配体及其制备方法 |
CN113880810B (zh) * | 2021-09-24 | 2023-02-28 | 厦门大学 | 一种核素标记的配合物及其制备方法和应用 |
TW202317541A (zh) | 2021-10-28 | 2023-05-01 | 行政院原子能委員會核能研究所 | 一種靶向成纖維細胞活化蛋白之化合物或其鹽,其製備方法及其用途 |
CN114163478B (zh) * | 2021-12-15 | 2023-03-24 | 北京师范大学 | 锝-99m标记含D-脯氨酸修饰的FAPI衍生物及制备方法和应用 |
CN116554146A (zh) * | 2022-01-29 | 2023-08-08 | 中国科学院生物物理研究所 | 一种FAP-α特异性放射性药物及其应用 |
CN115304582B (zh) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-α特异性肿瘤诊断显像剂 |
CN115160293B (zh) * | 2022-08-24 | 2023-12-08 | 北京师范大学 | 锝-99m标记含L-脯氨酸修饰的谷氨酸-脲衍生物及制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104667306B (zh) * | 2015-02-09 | 2018-02-02 | 刘丽 | 99mTc标记RGD多肽三聚体肿瘤显像药剂的化学结构及制备方法 |
CN106581700B (zh) * | 2016-12-02 | 2018-05-18 | 北京大学 | 一种靶向her2的新型多肽放射性药物及其制备方法和应用 |
WO2018222987A1 (en) * | 2017-06-01 | 2018-12-06 | Tarveda Therapeutics, Inc. | Targeted constructs |
CN108144072B (zh) * | 2017-12-27 | 2019-01-04 | 北京大学 | 用于诊断凝集素受体高表达肿瘤的放射性药物 |
SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
CN109045313B (zh) * | 2018-09-11 | 2020-02-18 | 北京大学 | 一种靶向her2的d型多肽放射性药物及制备方法 |
CN110743017B (zh) * | 2019-10-22 | 2021-03-09 | 北京大学 | 一种靶向半乳糖凝集素-1的放射性药物及其制备方法 |
CN111228521B (zh) * | 2020-01-17 | 2021-03-19 | 中国科学院生物物理研究所 | 一种Dar2多肽放射性药物及其制备方法 |
CN111991570B (zh) * | 2020-07-24 | 2021-05-18 | 北京大学 | 一种FAP-α特异性肿瘤诊断SPECT显像剂 |
-
2020
- 2020-07-24 CN CN202010725069.6A patent/CN111991570B/zh active Active
-
2021
- 2021-07-20 WO PCT/CN2021/107347 patent/WO2022017375A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN111991570A (zh) | 2020-11-27 |
WO2022017375A1 (zh) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111991570B (zh) | 一种FAP-α特异性肿瘤诊断SPECT显像剂 | |
CN116617420A (zh) | 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途 | |
CN109824765B (zh) | 68Ga标记AEEA修饰c-Met分子成像探针及制备与应用 | |
CN109942687B (zh) | 68Ga标记EACA修饰c-Met分子成像探针及制备与应用 | |
CN101985443A (zh) | 乙二半胱氨酸(ec)-药物结合物、组合物及用于组织特异性疾病显像的方法 | |
CN112043839A (zh) | 靶向转铁蛋白受体的放射性同位素标记多肽显像剂及其应用 | |
US20220211884A1 (en) | Rk polypeptide radiopharmaceutical targeting her2 and preparation method thereof | |
Lin et al. | Synthesis and evaluation of 18F labeled crizotinib derivative [18F] FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor | |
CN113583089A (zh) | 靶向肿瘤pd-l1的pet显像剂、其标记前体、制法和应用 | |
CN110496233B (zh) | 一种spect显像剂及其标记前体及其制备方法、组合物和用途 | |
Gao et al. | Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer | |
CN115583987A (zh) | 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用 | |
Zhou et al. | Synthesis and preclinical evaluation of novel 18F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts | |
WO2023236778A1 (zh) | 一种三功能化合物及其用途 | |
Sano et al. | Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method | |
Zhang et al. | Synthesis and biological evaluation of a new nitroimidazole-99mTc-complex for imaging of hypoxia in mice model | |
CA3188677A1 (en) | Imaging and targeting programmed death ligand-1 (pd-li) expression | |
Xu et al. | Iminodiacetic acid as bifunctional linker for dimerization of cyclic RGD peptides | |
CN105611948B (zh) | 对于癌症治疗效果的诊断剂 | |
US11795197B2 (en) | Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery | |
Ali et al. | Development of 99mTc-N4-NIM for molecular imaging of tumor hypoxia | |
Sun et al. | Synthesis and preclinical evaluation of a novel molecular probe [18F] AlF-NOTA-PEG2-Asp2-PDL1P for PET imaging of PD-L1 positive tumor | |
TWI572363B (zh) | 單光子發射型電腦斷層顯像放射性核種標記的rgd環肽三聚體、其製備方法及偵測腫瘤的方法 | |
CN115304582B (zh) | FAP-α特异性肿瘤诊断显像剂 | |
WO2024046469A1 (zh) | 环肽及其制备方法、包括其的复合物、及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220124 Address after: Room 02, 22nd floor, building 1, No. 36, Xiaoyun Road, Chaoyang District, Beijing 100027 Patentee after: Beijing Faber Xintian Pharmaceutical Technology Co.,Ltd. Address before: 100871 No. 5, the Summer Palace Road, Beijing, Haidian District Patentee before: Peking University |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 423-1, Building 1, No.1 Jinhe Road, Qinshan Street, Haiyan County, Jiaxing City, Zhejiang Province, 314303 Patentee after: Jiaxing Faber Xintian Pharmaceutical Technology Co.,Ltd. Address before: Room 02, 22nd floor, building 1, No. 36, Xiaoyun Road, Chaoyang District, Beijing 100027 Patentee before: Beijing Faber Xintian Pharmaceutical Technology Co.,Ltd. |